Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO).
暂无分享，去创建一个
E. Wardelmann | H. Joensuu | M. Schlemmer | P. Hohenberger | M. Eriksson | P. Reichardt | G. Ramadori | M. Leinonen | M. Sarlomo‐Rikala | S. Al-Batran | K. Sundby Hall | P. Bono | O. Monge | T. Alvegård | R. Kallio | A. Reichardt | J. Schutte | J. Hatrmann | B. Nilsson | Peter Reichardt | Giuliano Ramadori | P. Hohenberger | Petri Bono | M. Eriksson | E. Wardelmann | K. S. Hall | Jochen Schütte | Raija Kallio | Mika Leinonen